Medco Research submits NDA for ViaScint

Radiopharmaceutical developer Medco Research last month fileda new drug application for its ViaScint cardiac imaging agent.ViaScint is designed to predict changes in global ventricularfunction after coronary revascularization in patients undergoingcoronary artery bypass grafting (SCAN 1/17/96). Medco Research,of Research Triangle Park, NC, also developed cardiac stress agentAdenoscan, which is marketed by Fujisawa.